Meeting
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
Authors
Fadi Taza
Medstar Health Georgetown University, Baltimore, MD
Fadi Taza , Albert E Holler , Nabil Adra , Ryan Ashkar , Alexandra Sokolova , Adam Kessel , Nellie Nafissi , Pedro C. Barata , Diogo Assed Bastos , Oren Smaletz , Rahul Raj Aggarwal , Jacob E Berchuck , Panagiotis J. Vlachostergios , Christopher Su , Catherine Handy Marshall , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 100)
DOI
10.1200/JCO.2021.39.6_suppl.100
Abstract #
100
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Elena Castro
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2022 ASCO Genitourinary Cancers Symposium
Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
First Author: Charles J. Ryan